loading
전일 마감가:
$25.77
열려 있는:
$25.48
하루 거래량:
1.76M
Relative Volume:
0.45
시가총액:
$19.20B
수익:
$956.00K
순이익/손실:
$-221.32M
주가수익비율:
-80.78
EPS:
-0.32
순현금흐름:
$-142.25M
1주 성능:
+8.29%
1개월 성능:
-22.21%
6개월 성능:
+36.05%
1년 성능:
+498.38%
1일 변동 폭
Value
$25.12
$26.17
1주일 범위
Value
$22.85
$26.85
52주 변동 폭
Value
$2.10
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
명칭
Summit Therapeutics Inc
Name
전화
305-203-2034
Name
주소
601 BRICKELL KEY DRIVE, MIAMI
Name
직원
159
Name
트위터
@summitplc
Name
다음 수익 날짜
2025-02-24
Name
최신 SEC 제출 서류
Name
SMMT's Discussions on Twitter

SMMT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SMMT
Summit Therapeutics Inc
25.85 17.73B 956.00K -221.32M -142.25M -0.32
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 27.03B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 112.64B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 40.86M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 64.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 6.07B 0 -153.72M -103.81M -2.00

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-26 업그레이드 Citigroup Neutral → Buy
2025-03-21 개시 Cantor Fitzgerald Overweight
2025-03-12 개시 Evercore ISI Outperform
2025-02-28 개시 Goldman Buy
2025-01-08 개시 Truist Buy
2024-12-11 개시 Wells Fargo Overweight
2024-12-06 개시 Jefferies Buy
2024-11-04 개시 JMP Securities Mkt Outperform
2024-09-27 다운그레이드 Citigroup Buy → Neutral
2024-08-12 개시 H.C. Wainwright Buy
2024-05-07 개시 Citigroup Buy
2024-03-26 개시 Stifel Buy
2018-06-28 다운그레이드 Janney Buy → Neutral
2018-05-02 개시 Janney Buy
2018-04-12 재확인 Needham Buy
2018-02-13 개시 BTIG Research Buy
2018-01-04 개시 SunTrust Buy
2017-12-01 재개 H.C. Wainwright Buy
2016-11-16 재확인 RBC Capital Mkts Outperform
2016-10-05 재확인 Needham Buy
2016-09-16 개시 H.C. Wainwright Buy
2015-03-30 개시 Needham Buy
2015-03-30 개시 Oppenheimer Outperform
모두보기

Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스

pulisher
May 24, 2025

3 High-Flying Stocks That Could Soar Even More - Nasdaq

May 24, 2025
pulisher
May 22, 2025

Summit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025 - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Summit Therapeutics (SMMT) Receives Buy Rating and $33 Target | - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Summit Therapeutics (SMMT) Receives Buy Rating from Clear Street - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - The Globe and Mail

May 21, 2025
pulisher
May 19, 2025

Summit Therapeutics reports inducement grants - Medical Buyer

May 19, 2025
pulisher
May 18, 2025

Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money - Yahoo Finance

May 18, 2025
pulisher
May 16, 2025

(SMMT) Trading Report - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SMMT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

May 16, 2025
pulisher
May 15, 2025

BioNTech says bispecific antibody BNT327 is competitive against Summit's ivonescimab (BNTX:NASDAQ) - Seeking Alpha

May 15, 2025
pulisher
May 14, 2025

Dimensional Fund Advisors LP Acquires 160,592 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

May 14, 2025
pulisher
May 13, 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $37.40 Consensus PT from Analysts - Defense World

May 13, 2025
pulisher
May 12, 2025

Hsbc Holdings PLC Invests $188,000 in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

May 12, 2025
pulisher
May 11, 2025

Shareholders that lost money on Summit Therapeutics Inc.(SMMT) should contact Levi & Korsinsky about Securities Fraud InvestigationSMMT - ACCESS Newswire

May 11, 2025
pulisher
May 11, 2025

Summit Therapeutics (NASDAQ:SMMT) Upgraded at TD Cowen - Defense World

May 11, 2025
pulisher
May 10, 2025

Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud InvestigationSMMT - ACCESS Newswire

May 10, 2025
pulisher
May 10, 2025

Summit Therapeutics Q1 2025 slides: Strong cash position supports advancing Ivonescimab pipeline - Investing.com Canada

May 10, 2025
pulisher
May 09, 2025

SMMT ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Summit Therapeutics Inc. Shareholders Who Lost Money - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

Why Recursion Pharmaceuticals Stock Plummeted 24% This Week - The Motley Fool

May 09, 2025
pulisher
May 09, 2025

Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Summit Therapeutics (SMMT) Receives Positive Coverage from TD Co - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Summit Therapeutics (SMMT) Receives Positive Coverage from TD Cowen | SMMT Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Summit Therapeutics stock rating upgraded to Buy at TD Cowen By Investing.com - Investing.com India

May 08, 2025
pulisher
May 08, 2025

Summit Therapeutics stock rating upgraded to Buy at TD Cowen - Investing.com

May 08, 2025
pulisher
May 07, 2025

Can Summit Therapeutics Stock Double Your Money? - Nasdaq

May 07, 2025
pulisher
May 06, 2025

Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

(SMMT) Trading Advice - news.stocktradersdaily.com

May 06, 2025
pulisher
May 04, 2025

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial - MSN

May 04, 2025
pulisher
May 04, 2025

Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN

May 04, 2025
pulisher
May 04, 2025

Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey

May 04, 2025
pulisher
May 04, 2025

These 10 Firms Soared Last Week, Here’s Why - Insider Monkey

May 04, 2025
pulisher
May 03, 2025

Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN

May 03, 2025
pulisher
May 02, 2025

Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks

May 02, 2025
pulisher
May 02, 2025

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025
pulisher
May 02, 2025

This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025
pulisher
May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 | SMMT Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus

May 01, 2025

Summit Therapeutics Inc (SMMT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.15
price down icon 17.27%
$31.32
price down icon 3.63%
$587.61
price up icon 1.06%
$289.96
price up icon 0.33%
$4.25
price up icon 0.48%
$75.06
price up icon 3.26%
자본화:     |  볼륨(24시간):